Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Estramustine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.79 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.68 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.68 |
| ▸ | RECQL | P46063 | 2/20 | 0.93 |
| ▸ | BLM | P54132 | 2/20 | 0.93 |
| ▸ | ESR1 | P03372 | 6/20 | 0.79 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.79 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.79 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.79 |
| ▸ | DRD1 | P21728 | 1/20 | 0.79 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.79 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 5/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | ATM | Q13315 | 2/20 | 0.68 |
| ▸ | PGR | P06401 | 2/20 | 0.68 |
| ▸ | AR | P10275 | 2/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.68 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.68 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estramustine SCHEMBL36761 | 1.00 | RECQL (0.93) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL8342744 | 1.00 | RECQL (0.93) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL22129748 | 1.00 | RECQL (0.93) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL15710412 | 0.99 | RECQL (0.92) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL13753350 | 0.97 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL7200287 | 0.97 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL6353316 | 0.97 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL29349776 | 0.97 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL29374661 | 0.97 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL4252 | 0.97 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240165130-A1 | COMPOSITE DRUG PARTICLES AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-05-23 | — | — | US | disclosed |
| EP-2164871-A2 | ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS | Wyeth a Corporation of the State of Delaware (US) | 2010-03-24 | — | — | EP | disclosed |
| EP-2132224-A1 | CYCLIC RECEPTOR-ASSOCIATED PROTEIN (RAP) PEPTIDES | Raptor Pharmaceutical Inc (US) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008156713-A2 | ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS | WYETH (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008116171-A1 | CYCLIC RECEPTOR-ASSOCIATED PROTEIN (RAP) PEPTIDES | RAPTOR PHARMACEUTICAL INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| EP-1919505-A2 | SINGLE DOSE USE OF CD20-SPECIFIC BINDING MOLECULES | Trubion Pharmaceuticals, Inc. (US) | 2008-05-14 | — | — | EP | disclosed |
| EP-1912675-A2 | B-CELL REDUCTION USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES | Trubion Pharmaceuticals, Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007014238-A2 | SINGLE DOSE USE OF CD20-SPECIFIC BINDING MOLECULES | TRUBION PHARMACEUTICALS, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| WO-2007014278-A2 | B-CELL REDUCTION USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES | TRUBION PHARMACEUTICALS, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| EP-1667684-A1 | USE OF CHK1 INHIBITORS TO CONTROL CELL PROLIFERATION | ICOS Corporation (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005027907-A1 | USE OF CHK1 INHIBITORS TO CONTROL CELL PROLIFERATION | ICOS CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240165130-A1 | COMPOSITE DRUG PARTICLES AND USES THEREOF | LIPC, LIPA, FABP4 | KDR 4367/4885ADRA1A 802/4885OPRM1 1947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.